Atlas Trials

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Clinical trial NCT03217253 · WITHDRAWN

Trial details

NCT number
NCT03217253
Sponsor
National Cancer Institute (NCI)
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Ann Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaMetastatic Malignant Solid NeoplasmStage III Hepatocellular Carcinoma AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Unresectable Solid Neoplasm
Start date
2018-03-16
Primary completion
2019-09-19
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.